Optimising the design of phase II oncology trials: The importance of randomisation
- 9 December 2008
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 45 (2), 275-280
- https://doi.org/10.1016/j.ejca.2008.10.029
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase IIIJournal of Clinical Oncology, 2008
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening TrialsJournal of Clinical Oncology, 2005
- Predicting the Outcome of Phase III Trials using Phase II Data: A Case Study of Clinical Trial Simulation in Late Stage Drug DevelopmentBasic & Clinical Pharmacology & Toxicology, 2005
- Some Design Issues in Trials of Microbicides for the Prevention of HIV InfectionThe Journal of Infectious Diseases, 2004
- Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342Journal of Clinical Oncology, 2004
- A flexible design for multiple armed screening trialsStatistics in Medicine, 2001
- New designs for the selection of treatments to be tested in randomized clinical trialsStatistics in Medicine, 1994
- Incorporating historical control data in planning phase II clinical trialsStatistics in Medicine, 1990
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961